Untitled

Saito, Motoaki; Wada, Yasuhiko; Ikeda, Kazuyoshi; Wang, Z; He, Foster; Sd, Smith; Rm, Weiss; Latifpour, Jamshid

doi:10.1023/a:1007041909477

Cited by 12 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin treatment can normalize the altered prostatic weights and serum testosterone levels and molecular changes. These results suggest that the above molecular changes may be involved in the diabetesinduced prostate regression (54,99,124), which may affect male sexual response.…”

Section: T1dm and Ucodmentioning

confidence: 78%

Path of translational discovery of urological complications of obesity and diabetes

Daneshgari

Liu

Hanna-Mitchell

2017

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a prevalent chronic disease. Type 1 DM (T1DM) is a metabolic disorder that is characterized by hyperglycemia in the context of absolute lack of insulin, whereas type 2 DM (T2DM) is due to insulin resistance-related relative insulin deficiency. In comparison with T1DM, T2DM is more complex. The natural history of T2DM in most patients typically involves a course of obesity to impaired glucose tolerance, to insulin resistance, to hyperinsulinemia, to hyperglycemia, and finally to insulin deficiency. Obesity is a risk factor of T2DM. Diabetes causes some serious microvascular and macrovascular complications, such as retinopathy, nephropathy, neuropathy, angiopathy and stroke. Urological complications of obesity and diabetes (UCOD) affect quality of life, but are not well investigated. The urological complications in T1DM and T2DM are different. In addition, obesity itself affects the lower urinary tract. The aim of this perspective is to review the available data, combined with the experience of our research teams, who have spent a good part of last decade on studies of association between DM and lower urinary tract symptoms (LUTS) with the aim of bringing more focus to the future scientific exploration of UCOD. We focus on the most commonly seen urological complications, urinary incontinence, bladder dysfunction, and LUTS, in obesity and diabetes. Knowledge of these associations will lead to a better understanding of the pathophysiology underlying UCOD and hopefully assist urologists in the clinical management of obese or diabetic patients with LUTS.

show abstract

Section: T1dm and Ucodmentioning

confidence: 78%

Path of translational discovery of urological complications of obesity and diabetes

Daneshgari

Liu

Hanna-Mitchell

2017

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…In fact, this degenerative disease was described to affect not only sperm quality and function R S Tavares and others R14 (Bartak et al 1975, Padron et al 1984, Handelsman et al 1985, Vignon et al 1991, Baccetti et al 2002, Soudamani et al 2005, Amaral et al 2006, Scarano et al 2006, Agbaje et al 2007, Delfino et al 2007, Shrilatha & Muralidhara 2007a, Rama Raju et al 2012, Roessner et al 2012, Schoeller et al 2012a, Mangoli et al 2013 but also the hypothalamus-pituitary-gonadal axis (HPG) (Benitez & Perez Diaz 1985, Seethalakshmi et al 1987, Sudha et al 2000, Baccetti et al 2002, Lopez-Alvarenga et al 2002, Ballester et al 2004, Kim & Moley 2008, Schoeller et al 2012b, the testicular function and spermatogenesis (Cameron et al 1985, Gondos & Bevier 1995, Sanguinetti et al 1995, Sainio-Pollanen et al 1997, Ballester et al 2004, Arikawe et al 2006, Amaral et al 2009, Kianifard et al 2012, Schoeller et al 2012b, Wankeu-Nya et al 2013, Kyathanahalli et al 2014, Tavares et al 2016, the accessory organs (epididymis, prostate and seminal vesicles) (Murray et al 1981, Fukumoto et al 1993, Ikeda et al 2000, Saito et ...…”

Section: Diabetes Antidiabetic Drugs and Male Reproductive Functionmentioning

confidence: 99%

“…Studies in diabetic individuals or in diabetic conditions, provided important insights concerning the importance of insulin (its absence or excess) to the male reproductive system, with several studies reporting that the reproductive changes found in diabetic individuals could be reverted or attenuated by insulin treatment (Seethalakshmi et al 1987, Gondos & Bevier 1995, Ikeda et al 2000, Yamanaka et al 2003, Kim & Moley 2008, Singh et al 2009, Yonezawa et al 2009, Schoeller et al 2012a.…”

Section: Data From Studies In Diabetic Individuals/conditionsmentioning

confidence: 99%

Antidiabetic therapies and male reproductive function: where do we stand?

Tavares¹,

Escada-Rebelo²,

Silva³

et al. 2018

Reproduction

View full text Add to dashboard Cite

Diabetes mellitus has been increasing at alarming rates in recent years, thus jeopardizing human health worldwide. Several antidiabetic drugs have been introduced in the market to manage glycemic levels, and proven effective in avoiding, minimizing or preventing the appearance or development of diabetes mellitus-related complications. However, and despite the established association between such pathology and male reproductive dysfunction, the influence of these therapeutic interventions on such topics have been scarcely explored. Importantly, this pathology may contribute toward the global decline in male fertility, giving the increasing preponderance of diabetes mellitus in young men at their reproductive age. Therefore, it is mandatory that the reproductive health of diabetic individuals is maintained during the antidiabetic treatment. With this in mind, we have gathered the available information and made a critical analysis regarding the effects of several antidiabetic drugs on male reproductive function. Unlike insulin, which has a clear and fundamental role on male reproductive function, the other antidiabetic therapies' effects at this level seem incoherent. In fact, studies are highly controversial possibly due to the different experimental study approaches, which, in our opinion, suggests caution when it comes to prescribing such drugs to young diabetic patients. Overall, much is still to be determined and further studies are needed to clarify the safety of these antidiabetic strategies on male reproductive system. Aspects such as the effects of insulin levels variations, consequent of insulin therapy, as well as what will be the impact of the side effect hypoglycemia, common to several therapeutic strategies discussed, on the male reproductive system are still to be addressed.Reproduction (2018) 155 R13-R37

show abstract

“…In an additional study of similar design, treatment with insulin also reversed the upregulation of endothelin-1 binding sites in the vas deferens, apparently reflecting a homogenous population ET A receptors (Saito et al 1996 ). Subsequent studies also using a treatment design reported that treatment with insulin reversed greater expression of fibroblast growth factor-2 (also known as basic fibroblast growth factor) (Wang et al 2000 ), greater expression of transforming growth factor-β (TGF-β), and the related mRNAs, TGF-β1 and TGF-β2 (Ikeda et al 2000 ), and increased expression of endothelin receptors (about 80% ET A and 20% ET B receptors in all groups) (Saito et al 2000a ). BB/Wor rats spontaneously develop T1DM.…”

Section: Effects Of Antidiabetic Treatments On Lutd In Diabetesmentioning

confidence: 99%

Established and emerging treatments for diabetes-associated lower urinary tract dysfunction

Erdogan

Liu

Arioglu‐Inan

et al. 2022

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Dysfunction of the lower urinary tract (LUT) including urinary bladder and urethra (and prostate in men) is one of the most frequent complications of diabetes and can manifest as overactive bladder, underactive bladder, urinary incontinence, and as aggravated symptoms of benign prostate hyperplasia. We have performed a selective literature search to review existing evidence on efficacy of classic medications for the treatment of LUT dysfunction in diabetic patients and animals, i.e., α1-adrenoceptor and muscarinic receptor antagonists, β3-adrenoceptor agonists, and phosphodiesterase type 5 inhibitors. Generally, these agents appear to have comparable efficacy in patients and/or animals with and without diabetes. We also review effects of antidiabetic medications on LUT function. Such studies have largely been performed in animal models. In the streptozotocin-induced models of type 1 diabetes, insulin can prevent and reverse alterations of morphology, function, and gene expression patterns in bladder and prostate. Typical medications for the treatment of type 2 diabetes have been studied less often, and the reported findings are not yet sufficient to derive robust conclusions. Thereafter, we review animal studies with emerging medications perhaps targeting diabetes-associated LUT dysfunction. Data with myoinositol, daidzein, and with compounds that target oxidative stress, inflammation, Rac1, nerve growth factor, angiotensin II receptor, serotonin receptor, adenosine receptor, and soluble guanylyl cyclase are not conclusive yet, but some hold promise as potential treatments. Finally, we review nonpharmacological interventions in diabetic bladder dysfunction. These approaches are relatively new and give promising results in preclinical studies. In conclusion, the insulin data in rodent models of type 1 diabetes suggest that diabetes-associated LUT function can be mostly or partially reversed. However, we propose that considerable additional experimental and clinical studies are needed to target diabetes itself or pathophysiological changes induced by chronic hyperglycemia for the treatment of diabetic uropathy.

show abstract

Untitled

Cited by 12 publications

References 37 publications

Path of translational discovery of urological complications of obesity and diabetes

Path of translational discovery of urological complications of obesity and diabetes

Antidiabetic therapies and male reproductive function: where do we stand?

Established and emerging treatments for diabetes-associated lower urinary tract dysfunction

Contact Info

Product

Resources

About